<DOC>
	<DOCNO>NCT02617745</DOCNO>
	<brief_summary>The purpose GLIOPLAK evaluate predictive value biological test perform radio-chemotherapy phase patient suffer glioblastoma . The studied parameter variation platelet count radio-chemotherapy phase . The main objective identify early Stupp protocol group patient high risk undergo thrombocytopenia maintenance phase temozolomide . With result algorithm platelet monitoring patient treat Stupp protocol wil propose .</brief_summary>
	<brief_title>Impact Platelet Level Patients Treated Glioblastoma With Temozolomid</brief_title>
	<detailed_description>Glioblastoma common primitive cerebral tumor . Currently optimal treatment base multidisciplinary approach combine initial surgical resection , feasible , Stupp protocol . Stupp protocol consist two phase : first phase involve external radiotherapy concomitant oral temozolomide dose 75mg/m2 per day six week . After 4 week therapy break , maintenance phase begin temozolomide alone , period 6 cycle ( 1 cycle = 5 day 28 ) . The dose temozolomide 150mg/m2 first cycle follow 200 mg/m2 . One major limit toxicity temozolomide hematologic , especially thrombocytopenia . They occur around 15 20 % patient maintenance phase . Thrombocytopenia impact schedule Stupp protocol dose reduction even early discontinuation . Currently predictive marker thrombocytopenia maintenance phase identify . Such marker could major interest adapt biological clinical follow-up patient maintenance phase . We conduct retrospective analysis cohort patient suffer glioblastoma treat Stupp protocol . We find decrease platelet count radio-chemotherapy phase could highly predictive protocol change maintenance phase temozolomide due thrombocytopenia . The main objective GLIOPLAK prospectively confirm predictive value test evaluate prognostic impact occurrence thrombocytopenia &lt; 100,000/mm3 . Secondary objective GLIOPLAK describe limit toxicity maintenance phase , constitute prospective biological collection collect biological sample perform pharmacological analysis ( pharmacogenomics pharmacokinetics parameter ) .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Age Superior 18 year Inform consent form sign Newly diagnose ( histologically ) glioblastoma Stupp protocol treatment social insurance Not inform consent form sign participation another clinical trial cancer background hematological pathology patient guardianship , curatorship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stupp protocol , glioblastoma , thrombocytopenia</keyword>
</DOC>